A single trial readout just doubled a company’s market value in one session. Perplexity AI predicts the rerating continues, and the price prediction places Moderna...
In brief Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in...
